Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs
November 10, 2022 16:05 ET
|
Viracta Therapeutics, Inc.
Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open for enrollment at more than 50 sites worldwide; update on the first indication that may advance from Stage 1 to...
Viracta Therapeutics to Present at Upcoming Investor Conferences
November 02, 2022 16:05 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated cancers, today announced that company leadership is...
Viracta Therapeutics Announces New Employment Inducement Grant
September 19, 2022 16:30 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that, in connection...
Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China
December 04, 2018 01:00 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO and SHENZHEN, China, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a...
Viracta Announces Scientific Advisory Board Formation
September 25, 2018 08:00 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other...
Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat
April 11, 2018 08:00 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, April 11, 2018 (GLOBE NEWSWIRE) -- Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious...
NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
April 04, 2017 08:00 ET
|
Viracta Therapeutics, Inc.
CULVER CITY, Calif. and SAN DIEGO, April 04, 2017 (GLOBE NEWSWIRE) -- NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round...
Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics
November 30, 2016 08:00 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO and LONDON, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. announced completion of its acquisition of drug development candidate, VRx-3996, from Chroma Therapeutics, Ltd. ...